COLL

Collegium is a profitable, acquisition-built specialty pharma whose FY2025 revenue grew 23.6% to $781M — almost entirely on Jornay PM, the evening-dosed ADHD stimulant it picked up in the September 2024 Ironshore acquisition. The cash engine is real: operating cash flow jumped 60.7% to $329M, cash nearly tripled to $231M, ROE is 20.8%, and at a $1.14B market cap the stock trades at roughly 3.5x operating cash flow and 20.8x EPS — optically inexpensive for a company throwing off this much cash and buying back stock ($25.1M repurchased).

But the cheapness is earned, not free. Despite revenue up 23.6%, net income fell 9.1% to $62.9M and diluted EPS slipped 7% to $1.73 — operating income grew just 5.7%, so the model is running the wrong way at the margin as acquisition amortization and interest weigh on the bottom line. The MD&A makes the central threat explicit: a third-party generic of Nucynta IR was approved in January 2026, Hikma launched its authorized generic of Nucynta IR on February 25, 2026, and a Nucynta ER generic is expected in Q1 2026. Nucynta is a core pain product, so a meaningful slice of the revenue base is entering erosion right now. The portfolio is concentrated in Schedule II/III opioids (Xtampza ER, Nucynta, Belbuca), which carries inherent litigation and reputational overhang, and R&D was $0 in FY2024 — there is no internal pipeline, so future growth depends entirely on the next debt-funded acquisition.